Daily Endocrinology Research Analysis
Three studies advance endocrine science and practice: a translational JCI report introduces a humanized FSH-blocking antibody with multi-disease potential (osteoporosis, obesity, Alzheimer’s), a Nature Communications study uncovers a female-specific PGC-1α–ChREBPβ–phospholipid pathway controlling brown fat thermogenesis, and an Osteoporosis International analysis shows that combined assessment of testosterone and SHBG better predicts fracture risk in men. Together, they span therapeutic innovati
Summary
Three studies advance endocrine science and practice: a translational JCI report introduces a humanized FSH-blocking antibody with multi-disease potential (osteoporosis, obesity, Alzheimer’s), a Nature Communications study uncovers a female-specific PGC-1α–ChREBPβ–phospholipid pathway controlling brown fat thermogenesis, and an Osteoporosis International analysis shows that combined assessment of testosterone and SHBG better predicts fracture risk in men. Together, they span therapeutic innovation, mechanistic insight, and risk stratification.
Research Themes
- FSH blockade as a multi-disease therapeutic strategy (bone, adiposity, cognition)
- Sex-specific regulation of brown adipose thermogenesis via PGC-1α and phospholipid remodeling
- Integrated hormonal biomarkers (testosterone plus SHBG) for fracture risk prediction in men
Selected Articles
1. Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models.
This translational study details the crystal structure, GLP-grade formulation, pharmacokinetics, and preclinical efficacy/safety of a humanized FSH-blocking antibody. In mice, FSH blockade reduced fat mass and improved cognition without lowering estrogen; in African green monkeys, monthly dosing was well-tolerated with modest weight loss. The data support first-in-human testing for a multi-disease indication (osteoporosis, obesity, Alzheimer’s).
Impact: Provides IND-enabling, multi-species evidence for a first-in-class endocrine immunotherapy targeting FSH with potential to modify bone, adiposity, and cognition.
Clinical Implications: If human efficacy and safety are confirmed, FSH blockade could offer a hormone-sparing option for osteoporosis, obesity, and possibly Alzheimer’s disease in postmenopausal populations. Clinicians should watch for trial results and potential biomarker strategies (free FSH) to select responders.
Key Findings
- Solved the crystal structure of MS-Hu6 in complex with FSH, defining atomic-level binding.
- GLP-grade, ultra-high-concentration formulations (MS-Hu6 and Hf2) showed enhanced thermal and colloidal stability.
- 89Zr-MS-Hu6 had β-phase half-lives of 79 h (female mice) and 132 h (male mice) with tissue retention.
- FSH-blocking Hf2 reduced body weight and fat mass dose-dependently in female mice without lowering estrogen; improved cognition in AD-prone mice.
- Monthly MS-Hu6 dosing was safe in African green monkeys (n=4) with ~4% early weight loss.
Methodological Strengths
- Multisystem, multispecies validation (structural biology, GLP formulation, mouse efficacy/PK, nonhuman primate safety).
- Use of AD-prone mouse models to assess cognitive outcomes alongside metabolic endpoints.
Limitations
- Predominantly preclinical with small nonhuman primate sample size (n=4).
- Long-term safety, immunogenicity, and disease-specific efficacy in humans remain unknown.
Future Directions: Proceed to phase 1 trials to assess safety, PK/PD, and exploratory efficacy; define responder biomarkers (e.g., free FSH) and evaluate skeletal, adiposity, and cognitive endpoints.
There is growing evidence for direct actions of follicle-stimulating hormone (FSH) on tissues other than the ovaries and testes. Blocking FSH action, either genetically or pharmacologically, protects against bone loss, fat gain, and memory loss in mice. We thus developed a humanized FSH-blocking antibody, MS-Hu6, as a lead therapeutic for 3 diseases of public health magnitude - osteoporosis, obesity, and Alzheimer's disease (AD) - that track together in postmenopausal women. Here, we report the crystal structure of MS-Hu6 and its interaction with FSH in atomistic detail. Using our Good Laboratory Practice platform (21 CFR 58), we formulated MS-Hu6 and the murine equivalent, Hf2, at an ultra-high concentration; both formulated antibodies displayed enhanced thermal and colloidal stability. A single injection of 89Zr-labeled MS-Hu6 revealed a β phase t½ of 79 and 132 hours for female and male mice, respectively, with retention in regions of interest. Female mice injected subcutaneously with Hf2 displayed a dose-dependent reduction in body weight and body fat, in the face of reduced free (bioavailable) FSH and unperturbed estrogen levels. Hf2 also rescued recognition memory and spatial learning loss in a context- and time-dependent manner in AD-prone 3xTg and APP/PS1 mice. MS-Hu6 injected into African green monkeys (8 mg/kg) intravenously, and then subcutaneously at monthly intervals, was safe, and without effects on vital signs, blood chemistries, or blood counts. There was a notable approximately 4% weight loss in all 4 monkeys after the first injection, which continued in 2 of the monkeys. We thus provide Investigational New Drug-enabling data for a planned first-in-human study.
2. Testosterone, sex hormone-binding globulin, and fracture risk in men: evidence from observational and Mendelian randomization analyses.
In 162,786 UK Biobank men followed 13.3 years, higher bioavailable testosterone (accounting for SHBG) was linked to lower fracture risk (HR 0.72 for highest vs lowest quintile). Factorial Mendelian randomization showed that genetically higher testosterone combined with lower SHBG reduced fracture odds (OR 0.87), whereas either alone did not, underscoring the importance of assessing both hormones jointly.
Impact: Combines large-scale prospective epidemiology with factorial Mendelian randomization to refine endocrine risk stratification for fractures in men.
Clinical Implications: Fracture risk assessment in men may improve by jointly measuring testosterone and SHBG rather than testosterone alone; this could inform targeted prevention strategies and guide interpretation of testosterone therapy trials.
Key Findings
- Among 162,786 men, the highest quintile of bioavailable testosterone had a lower total fracture risk (adjusted HR 0.72 vs lowest quintile).
- Factorial Mendelian randomization: genetically higher testosterone combined with lower SHBG reduced fracture odds (OR 0.87; 95% CI 0.80–0.95).
- No association was observed when only testosterone was high or only SHBG was low, emphasizing their interaction.
Methodological Strengths
- Very large cohort with long follow-up and adjudicated fractures, adjusting for SHBG to estimate bioavailable testosterone.
- Use of factorial Mendelian randomization to strengthen causal inference about combined hormonal effects.
Limitations
- Observational measurements at baseline may not capture longitudinal hormone dynamics; residual confounding possible.
- Generalizability limited to men (UK Biobank) and fracture subtypes not stratified in detail.
Future Directions: Evaluate whether adding SHBG to testosterone improves fracture risk tools (e.g., FRAX), and test if SHBG-stratified testosterone therapy modifies fracture outcomes.
UNLABELLED: Both observational and factorial Mendelian randomization analysis revealed that the combined exposure to higher TT and lower SHBG was associated with decreased risk of fracture. These findings suggest that considering both TT and SHBG-rather than focusing on testosterone alone-may improve fracture risk assessment. PURPOSE: Lower total testosterone (TT) levels have been associated with increased fracture risk in aging men, yet the benefits of testosterone supplementation remain uncertain. This study aimed to assess the joint contributions of TT and sex hormone-binding globulin (SHBG) to fracture risk using both observational and genetic approaches. METHODS: We included 162,786 men from the UK Biobank, with baseline serum TT and SHBG measurements and genetic data. Cox proportional hazards models were used to estimate associations of TT and SHBG with incident fractures. A 2 × 2 factorial Mendelian randomization (MR) analysis was conducted to evaluate the combined genetic effects of increased TT and decreased SHBG on fracture risk. RESULTS: The median age at baseline was 59.0 years, and 7493 men experienced fractures during 13.3 years follow-up. The association between serum TT levels and incident fracture was significantly affected by adjustment for SHBG. Compared to the lowest quintile of Bio-T levels, the adjusted hazard ratio (HR) for total fracture in the highest quintile was 0.72 (95% CI: 0.67, 0.78). In factorial MR analysis, men with genetically higher TT and lower SHBG had significantly lower odds of total fracture (OR: 0.87, 95% CI: 0.80-0.95) compared to those with genetically lower TT and higher SHBG. No association was observed in groups with only high TT or only low SHBG. CONCLUSION: Our findings suggest that the interplay between TT and SHBG is important in determining fracture risk, highlighting the potential clinical value of jointly assessing them to improve fracture risk stratification in men.
3. Sex difference in BAT thermogenesis depends on PGC-1α-mediated phospholipid synthesis in mice.
Inducible adipocyte-specific PGC-1α deletion impaired BAT thermogenesis specifically in female mice, linked to reduced ChREBPβ and de novo lipogenesis gene expression, mitochondrial defects, and altered phospholipid composition. BAT-specific ChREBPβ knockdown recapitulated these effects in females, revealing a sex-specific PGC-1α–ChREBPβ–phospholipid pathway controlling thermogenesis.
Impact: Reveals a mechanistic, sex-specific axis linking PGC-1α, ChREBPβ, and phospholipid remodeling to brown fat thermogenesis, informing tailored anti-obesity strategies.
Clinical Implications: Sex-specific pathways in energy expenditure suggest future precision therapies targeting PGC-1α/ChREBPβ or mitochondrial phospholipid remodeling, particularly in women, to enhance thermogenesis and treat obesity.
Key Findings
- Adipocyte-specific inducible PGC-1α knockout reduced BAT thermogenesis and caused mitochondrial defects only in female mice.
- Female KO mice showed decreased ChREBPβ and de novo lipogenesis gene expression; BAT-specific ChREBPβ knockdown reduced thermogenesis in females.
- Lipidomics implicated increased ether-linked phosphatidylethanolamine and cardiolipin remodeling as downstream of PGC-1α.
Methodological Strengths
- Inducible, adipocyte-specific gene knockout with BAT-focused phenotyping and parallel BAT-specific knockdown experiments.
- Integration of lipidomics with mitochondrial morphology and functional thermogenesis assays.
Limitations
- Findings are in mice; human validation is lacking.
- Sample sizes and effect sizes by group are not detailed in the abstract.
Future Directions: Validate the PGC-1α–ChREBPβ–phospholipid axis in human BAT and test pharmacologic or nutritional modulators to enhance thermogenesis, prioritizing sex-specific responses.
Brown adipose tissue (BAT), a thermogenic tissue that plays an important role in systemic energy expenditure, has histological and functional sex differences. BAT thermogenic activity is higher in female mice than in male mice. However, the molecular mechanism underlying this functional sex difference has not been fully elucidated. Herein, we demonstrate the role and mechanism of PGC-1α in this sex difference. Inducible adipocyte-specific PGC-1α knockout (KO) mice display mitochondrial morphological defects and decreased BAT thermogenesis only in females. Expression of carbohydrate response-element binding protein beta (Chrebpβ) and its downstream de novo lipogenesis (DNL)-related genes are both reduced only in female KO mice. BAT-specific knockdown of ChREBPβ displays decreased DNL-related gene expression and mitochondrial morphological defects followed by reduced BAT thermogenesis in female wild-type mice. Lipidomics reveals that, PGC-1α increases ether-linked phosphatidylethanolamine (PE) and cardiolipin(18:2)